Literature DB >> 19941021

Interaction of the heptavalent pneumococcal conjugate vaccine and the use of individual antibiotics among children on nasopharyngeal colonization with erythromycin-resistant Streptococcus pneumoniae.

Ioanna N Grivea1, Alexandra G Tsantouli, Denise C Chryssanthopoulou, George A Syrogiannopoulos.   

Abstract

The purpose of this study was to assess the complex interaction of the heptavalent pneumococcal conjugate vaccine (PCV7) and individual classes of antimicrobial agents on the nasopharyngeal carriage of erythromycin-resistant pneumococci within the day-care center population. Between February 2005 and May 2007, nasopharyngeal cultures for Streptococcus pneumoniae were obtained from 1,829 day-care center attendees in Central Greece. Thirty-one percent of the pneumococci were erythromycin-resistant; 85.2% of these isolates were also penicillin-nonsusceptible. PCV7 immunization was associated with decreased carriage of erythromycin-resistant PCV7 serotypes but not with an overall decrease in erythromycin-resistant S. pneumoniae colonization. The largest decline in the carriage of erythromycin-resistant pneumococci, particularly of PCV7 serotypes, was observed among vaccinated attendees who had not been exposed to antimicrobials within the preceding 3 months. Exposure to macrolides, 90% clarithromycin, significantly correlated with erythromycin resistance (adjusted odds ratio [AOR] = 2.08, 95% confidence interval [CI] = 1.38-3.12). There was a trend toward an association between the use of oral cephalosporins, other than cefprozil and cefaclor, and colonization with erythromycin-resistant pneumococci (AOR = 1.91, 95% CI = 0.92-3.96). Penicillins had a nonsignificant correlation with the carriage of erythromycin-resistant pneumococci (AOR = 1.17, 95% CI = 0.80-1.71). Despite the widespread PCV7 immunization, the antibiotic pressure, particularly of macrolides, continues to cause dissemination of erythromycin-resistant, commonly multidrug-resistant, pneumococci within the day-care center population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941021     DOI: 10.1007/s10096-009-0826-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Antimicrobial use and serotype distribution of nasopharyngeal Streptococcus pneumoniae isolates recovered from Greek children younger than 2 years old.

Authors:  George A Syrogiannopoulos; George D Katopodis; Ioanna N Grivea; Nicholas G Beratis
Journal:  Clin Infect Dis       Date:  2002-10-21       Impact factor: 9.079

2.  Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillance.

Authors:  S Nunes; R Sá-Leão; J Carriço; C R Alves; R Mato; A Brito Avô; J Saldanha; J S Almeida; I Santos Sanches; H de Lencastre
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.

Authors:  David J Farrell; Keith P Klugman; Michael Pichichero
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

4.  Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

Authors:  Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

5.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

6.  Impact of amoxicillin on pneumococcal colonization compared with other therapies for acute otitis media.

Authors:  Philip Toltzis; Michael Dul; Mary Ann O'Riordan; Hasida Toltzis; Jeffrey L Blumer
Journal:  Pediatr Infect Dis J       Date:  2005-01       Impact factor: 2.129

7.  Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations.

Authors:  Matthew H Samore; Marc Lipsitch; Stephen C Alder; Bassam Haddadin; Greg Stoddard; Jacquelyn Williamson; Katherine Sebastian; Karen Carroll; Onder Ergonul; Yehuda Carmeli; Merle A Sande
Journal:  Am J Epidemiol       Date:  2005-11-30       Impact factor: 4.897

8.  Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004).

Authors:  Matsuhisa Inoue; David J Farrell; Kenichi Kaneko; Kouji Akizawa; Shinichi Fujita; Mitsuo Kaku; Jun Igari; Keizo Yamaguchi; Kiyoharu Yamanaka; Mitsuharu Murase; Seishi Asari; Yoichi Hirakata; Hisashi Baba; Hideyuki Itaha
Journal:  Microb Drug Resist       Date:  2008-06       Impact factor: 3.431

9.  Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

10.  Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.

Authors:  Ron Dagan; Noga Givon-Lavi; Orly Zamir; Drora Fraser
Journal:  Pediatr Infect Dis J       Date:  2003-06       Impact factor: 2.129

View more
  2 in total

1.  Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine.

Authors:  S Maraki; G Samonis; E Galanakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-10       Impact factor: 3.267

2.  Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece.

Authors:  Ioanna N Grivea; Alexia Sourla; Eleni Ntokou; Denise C Chryssanthopoulou; Alexandra G Tsantouli; George A Syrogiannopoulos
Journal:  BMC Infect Dis       Date:  2012-10-11       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.